Analysts Set Simulations Plus, Inc. (NASDAQ:SLP) Target Price at $24.40

Simulations Plus, Inc. (NASDAQ:SLP) has been assigned an average recommendation of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $24.40.

SLP has been the subject of several research analyst reports. Stephens dropped their target price on shares of Simulations Plus from $28.00 to $20.00 and set an “overweight” rating for the company in a research report on Tuesday, July 15th. Zacks Research raised shares of Simulations Plus to a “hold” rating in a research report on Tuesday, August 12th. TD Cowen initiated coverage on shares of Simulations Plus in a research report on Tuesday, September 30th. They issued a “hold” rating and a $16.00 target price for the company. KeyCorp downgraded shares of Simulations Plus from an “overweight” rating to a “sector weight” rating in a research report on Tuesday, July 15th. Finally, Cowen initiated coverage on shares of Simulations Plus in a research report on Tuesday, September 30th. They issued a “hold” rating for the company.

Institutional Investors Weigh In On Simulations Plus

A number of institutional investors have recently modified their holdings of SLP. GAMMA Investing LLC grew its position in shares of Simulations Plus by 20,727.1% during the 1st quarter. GAMMA Investing LLC now owns 17,703 shares of the technology company’s stock valued at $434,000 after buying an additional 17,618 shares during the last quarter. Rhumbline Advisers grew its position in shares of Simulations Plus by 2.1% during the 1st quarter. Rhumbline Advisers now owns 66,222 shares of the technology company’s stock valued at $1,624,000 after buying an additional 1,334 shares during the last quarter. Fifth Third Bancorp grew its position in shares of Simulations Plus by 33.8% during the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock valued at $36,000 after buying an additional 375 shares during the last quarter. Azzad Asset Management Inc. ADV bought a new stake in shares of Simulations Plus during the 1st quarter valued at about $436,000. Finally, North Star Investment Management Corp. bought a new stake in shares of Simulations Plus during the 1st quarter valued at about $1,300,000. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Price Performance

Simulations Plus stock opened at $15.43 on Thursday. Simulations Plus has a 12-month low of $12.39 and a 12-month high of $37.67. The company has a market capitalization of $310.61 million, a price-to-earnings ratio of -4.90 and a beta of 0.99. The firm’s fifty day moving average price is $14.66 and its 200 day moving average price is $21.00.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Monday, July 14th. The technology company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.19. Simulations Plus had a negative net margin of 78.63% and a positive return on equity of 11.62%. The firm had revenue of $20.36 million for the quarter, compared to the consensus estimate of $22.83 million. During the same quarter in the previous year, the firm posted $0.27 EPS. The firm’s quarterly revenue was up 9.8% on a year-over-year basis. Analysts forecast that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.